Dana-Farber Cancer Institute (DFCI)
Welcome,         Profile    Billing    Logout  
 45 Trials 
76 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hodi, F Stephen
NCT00809588: Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)

Completed
1
84
US
Autologous, lethally irradiated melanoma cells
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital
Melanoma
09/16
02/20
NCT00790010: Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Checkmark Data
May 2011 - May 2011: Data
Completed
1
46
US
Bevacizumab Plus Ipilimumab Cohort 1, Bevacizumab- also known as Avastin, Ipilimumab-also known as MDX-010 or MDX-101 & marketed as Yervoy, Bevacizumab Plus Ipilimumab Cohort 2, Bevacizumab Plus Ipilimumab Cohort 3, Bevacizumab Plus Ipilimumab Cohort 4
Dana-Farber Cancer Institute, Genentech, Inc., Bristol-Myers Squibb
Melanoma
06/18
06/18
NCT01753089: Dendritic Cell Activating Scaffold in Melanoma

Active, not recruiting
1
23
US
WDVAX
Dana-Farber Cancer Institute
Melanoma
12/24
12/24
Jacene, Heather A
NCT06479187: PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Not yet recruiting
4
20
US
18F-rhPSMA-7.3, PET/CT
Brigham and Women's Hospital, Dana-Farber Cancer Institute, Blue Earth Diagnostics
Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
06/26
06/27
NCT06099093: Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Recruiting
4
30
US
18F-DCFPyl, [F18]-Piflufolastat, Pylarify, 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]- pentyl}ureido)-pentanedioic acid
Brigham and Women's Hospital, Progenics Pharmaceuticals, Inc.
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma
12/24
12/25
ACTION-1, NCT05477576: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
07/25
07/28
DIRECT, NCT05710328: Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The Trial

Recruiting
2
235
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Surgical Procedure, Operation, Surgery, Surgery Type, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
ECOG-ACRIN Cancer Research Group
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
03/25
03/25
NCT04316117: Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Active, not recruiting
2
138
Europe, US
Computed Tomography, CAT, CAT scan, computerized axial tomography, Computerized Tomography, CT, CT scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
08/27
08/27
NCT04018053: 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Active, not recruiting
1
16
US
18F-fluciclovine, Axumin, PET/CT
Dana-Farber Cancer Institute, Blue Earth Diagnostics
Bladder Cancer, Urothelial Carcinoma
06/24
12/24
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Recruiting
1
110
Canada, US
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Fusion Pharmaceuticals Inc., AstraZeneca
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/26
12/27
NCT06062745: Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Recruiting
1
30
US
18F-fluciclovine, Axumin, PET/CT
Brigham and Women's Hospital, Blue Earth Diagnostics
Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
09/26
09/28
Degar, Barbara
NCT02205762 / 2011-001699-20: LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Recruiting
2/3
1400
US
Prednisone, Vinblastine, Velban®, Vincaleukoblastine Sulfate, mercaptopurine, -Purinethol®, -6-MP, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, Cytarabine, Ara-C, 2-chlorodeoxyadenosine, 2-CdA, Cladribin®, Leustatin®, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin, IVIG
North American Consortium for Histiocytosis, Histiocyte Society
Langerhans Cell Histiocytosis
07/25
07/25
NCT02425904: Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Active, not recruiting
2
25
Canada, US
Clofarabine, Clofarex, Clolar
Dana-Farber Cancer Institute, Sanofi, St. Baldrick's Foundation, Cookies for Kids' Cancer, North American Consortium for Histiocytosis
Langerhans Cell Histiocytosis
01/20
01/25
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/24
12/29
NCT04551131: Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting
1/2
62
US
Ruxolitinib, Jakafi®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16
St. Jude Children's Research Hospital, Incyte Corporation, North American Consortium for Histiocytosis, Cures Within Reach
Hemophagocytic Lymphohistiocytosis
08/25
08/26
Ott, Patrick
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Suspended
2
220
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
05/28
05/28
NCT02071992: Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Not yet recruiting
1
24
US
Tremelimumab, CP-675,206, Ticilimumab, MEDI3617, MEDI-3617
F. Stephen Hodi, MD, MedImmune LLC
Metastatic Melanoma
06/17
02/19
NCT02141542: Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Hourglass Jan 2017 - Dec 2017 : Tremelimumab and MEDI3617 combination in unresectable melanoma
Completed
1
15
US
Tremelimumab, CP-675,206, Ticilimumab, MEDI3617, MEDI-3617
F. Stephen Hodi, MD, MedImmune LLC
Metastatic Melanoma
09/20
09/20
NCT03929029: Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Active, not recruiting
1
11
US
Nivolumab (480 mg infusion), Opdivo, NeoVax plus Montanide, Ipilimumab, Yervoy
Dana-Farber Cancer Institute, National Cancer Institute (NCI)
Cutaneous Melanoma
12/22
09/28
CTX-8371-001, NCT06150664: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Recruiting
1
55
US
CTX-8371
Compass Therapeutics
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
10/25
04/26
AIM-NIVO, NCT03816345: Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Recruiting
1
300
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
08/26
08/26
NCT02950766: NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Active, not recruiting
1
19
US
NeoVax, neoantigen vaccine, Ipilimumab, Yervoy
Patrick Ott, MD, PhD, Bristol-Myers Squibb, Oncovir, Inc.
Kidney Cancer
12/24
05/30
NCT04930783: NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Recruiting
1
30
US
CDX-301, NEOVAX, Nivolumab, Opdivo, Pembrolizumab, Keytruda
Dana-Farber Cancer Institute, Celldex Therapeutics
Melanoma, Metastatic Melanoma
01/25
01/27
Liu, David MT
TAVR-HBE, NCT04982406: Transcatheter Aortic Valve Replacement (TAVR) Effects on Cardiac Conduction System

Recruiting
N/A
410
US
Transcatheter aortic valve replacement
Beth Israel Deaconess Medical Center
Aortic Stenosis, Transcatheter Aortic Valve Replacement, Heart Block
12/24
12/24
STAR-T, NCT04976530: Safe and Timely Antithrombotic Removal - Ticagrelor

Completed
N/A
140
Canada, US
DrugSorb-ATR system, Sorbent hemoperfusion system, Sham comparator
CytoSorbents, Inc
Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
08/23
08/23
MAGMAP, NCT05899985: Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation

Recruiting
N/A
60
RoW
FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System
Ferronova Pty Ltd, Royal Adelaide Hospital, Austin Health, Flinders Medical Centre, Peter MacCallum Cancer Centre, Australia, South Australian Health and Medical Research Institute
Gastric Cancer, Esophageal Cancer
02/25
02/30
Hodi, Stephen
NCT05428007: Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Recruiting
2
69
US
Sarilumab, REGN88, Ipilimumab Injection, BMS-734016, MDX010, MDX-CTLA4, Nivolumab/Relatlimab, BMS-986213
NYU Langone Health
Melanoma, Unresectable Melanoma
06/25
12/25
MCLA-145-CL01, NCT03922204: A Study of Bispecific Antibody MCLA-145 in Patients with Advanced or Metastatic Malignancies

Active, not recruiting
1
238
Europe, US
MCLA-145, bispecific, Pembrolizumab (Keytruda)
Merus N.V., Incyte Corporation
Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
12/25
12/25
NCT03239145 / 2006-004036-71: Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Active, not recruiting
1
60
US
Pembrolizumab, Keytruda, Trebananib, AMG 386
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC, Amgen
Advanced Solid Tumor
02/25
08/25
NCT05496595: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Terminated
1
5
US
DCBY02
DynamiCure Biotechnology
Advanced or Metastatic Solid Tumors
02/24
02/24
NCT05785754: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
257
US, RoW
DCSZ11, Pembrolizumab
DynamiCure Biotechnology
Advanced or Metastatic Solid Tumors
04/25
05/25
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
Haq, Rizwan
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT04109456: IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Recruiting
1
120
US, RoW
IN10018, BI 853520, Cobimetinib, Cotellic, Atezolizumab
InxMed (Shanghai) Co., Ltd.
Metastatic Melanoma
06/24
09/24
Buchbinder, Elizabeth
NCT03417739: A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Active, not recruiting
2
13
US
BVD-523, Ulixertinib
Dana-Farber Cancer Institute, BioMed Valley Discoveries, Inc
Uveal Melanoma
05/20
08/25
NCT04305145: Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Recruiting
2
42
US
Infliximab, AVSOLA, Ixifi, Remicade, Renflexis, Methylprednisolone, Solu-Medrol, Duralone, Medralone, Medrol, M-Prednisol, Prednisone, Deltasone, Prednicot, predniSONE Intensol, Rayos, Sterapred, Sterapred DS
Massachusetts General Hospital, Dana-Farber Cancer Institute
Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
06/30
06/30
NCT05111574: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting
2
99
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Mucosal Melanoma of the Urinary System, Nasopharyngeal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma
12/24
12/24
NCT04703426: Sargramostim (GM-CSF) + PD-1

Withdrawn
2
30
NA
Sargramostim (GM-CSF), Leukine, Pembrolizumab (anti-PD-1), Keytruda
Dana-Farber Cancer Institute, Partner Therapeutics (PTx)
Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
06/24
06/25
NCT04356729: A Phase II Trial of PD-L1 Therapy Combined with Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Recruiting
2
30
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Mvasi
Elizabeth Buchbinder, MD, Genentech, Inc.
Clinical Stage III Cutaneous Melanoma AJCC V8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
12/24
09/25
Neo-MEL-T, NCT04139902: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) Vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Recruiting
2
62
US
Dostarlimab (TSR-042) (singly), Dostarlimab, Dostarlimab (TSR-042) and TSR-022 (combination)
Diwakar Davar, Tesaro, Inc.
Melanoma Stage III, Melanoma Stage IV
09/25
04/29
NCT03101254 / 2017-000429-10: LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Completed
1/2
5
US
LY3022855, Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Dana-Farber Cancer Institute, Eli Lilly and Company
Melanoma
10/20
11/20
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
CA101-001, NCT04423029 / 2021-000038-33: A Study of DF6002 Alone and in Combination With Nivolumab

Recruiting
1/2
473
Europe, US, RoW
DF6002, Nivolumab, Opdivo
Dragonfly Therapeutics
Solid Tumors
07/24
12/25
NCT03455764: MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Completed
1/2
6
US
MCS110, Dabrafenib, Tafinlar, Trametinib, Mekinist
Dana-Farber Cancer Institute, Novartis
Melanoma
09/23
09/23
IMM1104-101, NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
CFT1946-1101, NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
Syntrix-SX682-Melanoma-101, NCT03161431: SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Checkmark Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Oct 2020 - Oct 2020: Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Recruiting
1
77
US
SX-682, Pembrolizumab, KEYTRUDA
Syntrix Biosystems, Inc., Massachusetts General Hospital, National Cancer Institute (NCI), Dana-Farber Cancer Institute, Mayo Clinic, University of Rochester, M.D. Anderson Cancer Center, University of Miami
Melanoma Stage III, Melanoma Stage IV
06/25
06/26
NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma

Terminated
1
76
Europe, US
FHD-286
Foghorn Therapeutics Inc.
Metastatic Uveal Melanoma
11/23
11/23
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27
Izar, Benjamin
NCT05116683: ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma

Terminated
2
4
US
ATX-101, ATX-101 drug substance
Benjamin Izar
Leiomyosarcoma, Liposarcoma
10/22
10/22
AAAQ8661, NCT02978859: Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Completed
2
29
US
MGCD516, Sitravatinib
Columbia University, Mirati Therapeutics Inc.
Liposarcoma, Metastatic Liposarcoma
01/20
12/21
IMC-F106C-101, NCT04262466 / 2019-004046-16: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Recruiting
1/2
727
Europe, Canada, US, RoW
Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors
Immunocore Ltd
Select Advanced Solid Tumors
02/26
08/26
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Active, not recruiting
1
67
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
06/25
06/27
Henry, Jason
TWINPEAK, NCT05482893: PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the Study)

Recruiting
1/2
114
US
PT886, Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
12/25
04/26
IMM6415-101, NCT06208124: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Recruiting
1/2
240
US
IMM-6-415
Immuneering Corporation
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
06/27
07/27
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
MDX-2001-101, NCT06239194: Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Recruiting
1/2
115
US
MDX2001
ModeX Therapeutics, An OPKO Health Company
Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer
08/28
02/29
SKYBRIDGE, NCT05652686: A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the Study)

Recruiting
1/2
61
US
PT217
Phanes Therapeutics
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
01/25
06/25
NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
313
US
TAK-500, Pembrolizumab
Takeda
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
08/26
08/26
GV20-0251-100, NCT05669430: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies

Recruiting
1/2
365
US
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], MK-3475
GV20 Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
12/26
09/27
INCLINE-101, NCT05399654: A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
72
US, RoW
TAC-001
Tallac Therapeutics
Advanced or Metastatic Solid Tumors
01/26
05/26
IMM1104-101, NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
NCT05159700: A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Recruiting
1
46
US
PRJ1-3024
Zhuhai Yufan Biotechnologies Co., Ltd
Advanced Solid Tumor, Advanced Solid Malignancies
02/24
08/24
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Recruiting
1
155
Canada, US, RoW
YL211
MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche
Advanced Solid Tumors
04/27
04/29
NCT06415487: ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Not yet recruiting
1
30
US
Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab
Acepodia Biotech, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
12/26
03/27
NCT06582017: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Recruiting
1
100
US
QXL138AM Injection every 2 weeks by IV Infusion
Nammi Therapeutics Inc
Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
12/27
05/28
SRN-707-001, NCT05037149: Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Active, not recruiting
1
50
US
STP707, STP707 Powder for Injection
Sirnaomics
Solid Tumor
03/24
03/24
NCT06586515: A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
530
Europe, Canada, Japan, US
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Recruiting
1
572
Europe, Canada, US
SGN-B7H4V, Pembrolizumab, Keytruda
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
11/27
11/27
NCT05948826: First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Recruiting
1
70
Canada, US
TORL-3-600
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Colorectal Cancer
09/25
09/26
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
ST316-101, NCT05848739: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Recruiting
1
130
US
ST316, FOLFIRI regimen & bevacizumab, FOLFIRI, Fruquintinib, Lonsurf & bevacizumab
Sapience Therapeutics
Colon Cancer, Metastatic Colon Cancer
05/26
05/27
NCT05377528: Study of AGEN1571 in Participants With Advanced Solid Tumors

Active, not recruiting
1
22
US
AGEN1571, Balstilimab, AGEN2034, Botensilimab, AGEN1181
Agenus Inc.
Advanced Solid Tumor
01/27
01/27
Cobanoglu, Z Esra
TWINPEAK, NCT05482893: PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the Study)

Recruiting
1/2
114
US
PT886, Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
12/25
04/26
NCT05797805: A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Recruiting
1/2
108
Canada, US
Tegavivint, BC2059, Pembrolizumab, Keytruda
Iterion Therapeutics
Advanced Hepatocellular Carcinoma
05/26
06/26

Download Options